Although irisin is not an approved compound for the treatment of DM, a recent study has provided evidence that irisin could exert therapeutic potential in obesity and type 2 DM by stimulating the “browning” of white adipose tissue [22]. Here, FNDC5 is linked to obesity due to melanocortin 4 receptor deficiency.